Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active surveillance with or without 6 months apalutamide in low-risk prostate cancer
2016-001266-29Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Institut Paoli-Calmettes. Primary endpoint: Time to initiate local treatment. Started Feb 2017; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-001266-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001266-29.